By SPC News Staff
People with extremely high levels of triglycerides and a specific genetic profile saw a substantial reduction in fasting triglyceride levels after evinacumab-dgnb (Evkeeza, Regeneron) compared with those taking placebo, in a study presented at the American College of Cardiology’s 2021 Annual Scientific Session & Expo (session 406-19 ).
The phase 2 trial enrolled 51 patients with hypertriglyceridemia at 17 sites in four countries in North America and Europe. Patients